Bashir Asma, Binderup Tina, Vestergaard Mark Bitsch, Broholm Helle, Marner Lisbeth, Ziebell Morten, Fugleholm Kåre, Kjær Andreas, Law Ian
Department of Clinical Physiology, Nuclear Medicine and PET, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen Ø, Denmark.
Cluster for Molecular Imaging, University of Copenhagen, Copenhagen, Denmark.
Eur J Nucl Med Mol Imaging. 2020 Jun;47(6):1496-1509. doi: 10.1007/s00259-020-04704-2. Epub 2020 Feb 11.
Positron emission tomography (PET) with 3'-deoxy-3'-[F]fluorothymidine ([F]FLT) provides a noninvasive assessment of tumour proliferation in vivo and could be a valuable imaging modality for assessing malignancy in meningiomas. We investigated a range of static and dynamic [F]FLT metrics by correlating the findings with cellular biomarkers of proliferation and angiogenesis.
Seventeen prospectively recruited adult patients with intracranial meningiomas underwent a 60-min dynamic [F]FLT PET following surgery. Maximum and mean standardized uptake values (SUV, SUV) with and without normalization to healthy brain tissue and blood radioactivity obtained from 40 to 60 min summed dynamic images (PET) and ~ 60-min blood samples were calculated. Kinetic modelling using a two-tissue reversible compartmental model with a fractioned blood volume (V) was performed to determine the total distribution volume (V). Expressions of proliferation and angiogenesis with key parameters including Ki-67 index, phosphohistone-H3 (phh3), MKI67, thymidine kinase 1 (TK1), proliferating cell nuclear antigen (PCNA), Kirsten RAt Sarcoma viral oncogene homolog (KRAS), TIMP metallopeptidase inhibitor 3 (TIMP3), and vascular endothelial growth factor A (VEGFA) were determined by immunohistochemistry and/or quantitative polymerase chain reaction.
Immunohistochemistry revealed 13 World Health Organization (WHO) grade I and four WHO grade II meningiomas. SUV and SUV normalized to blood radioactivity from PET and blood sampling, and V were able to significantly differentiate between WHO grades with the best results for maximum and mean tumour-to-whole-blood ratios (sensitivity 100%, specificity 94-95%, accuracy 99%; P = 0.003). Static [F]FLT metrics were significantly correlated with proliferative biomarkers, especially Ki-67 index, phh3, and TK1, while no correlations were found with VEGFA or V. Using Ki-67 index with a threshold > 4%, the majority of [F]FLT metrics showed a high ability to identify aggressive meningiomas with SUV demonstrating the best performance (sensitivity 80%, specificity 81%, accuracy 80%; P = 0.024).
[F]FLT PET could be a useful imaging modality for assessing cellular proliferation in meningiomas.
3'-脱氧-3'-[F]氟胸腺嘧啶核苷([F]FLT)正电子发射断层扫描(PET)可在体内对肿瘤增殖进行无创评估,可能是评估脑膜瘤恶性程度的一种有价值的成像方式。我们通过将研究结果与增殖和血管生成的细胞生物标志物相关联,研究了一系列静态和动态的[F]FLT指标。
17例前瞻性招募的颅内脑膜瘤成年患者术后接受了60分钟的动态[F]FLT PET检查。计算了40至60分钟的总动态图像(PET)和约60分钟血样中获得的最大和平均标准化摄取值(SUV、SUV),包括有无根据健康脑组织和血液放射性进行归一化处理的情况。使用具有分流血容量(V)的双组织可逆房室模型进行动力学建模,以确定总分布容积(V)。通过免疫组织化学和/或定量聚合酶链反应确定增殖和血管生成相关关键参数的表达,包括Ki-67指数、磷酸组蛋白-H3(phh3)、MKI67、胸苷激酶1(TK1)、增殖细胞核抗原(PCNA)、 Kirsten大鼠肉瘤病毒癌基因同源物(KRAS)、金属蛋白酶组织抑制剂3(TIMP3)和血管内皮生长因子A(VEGFA)。
免疫组织化学显示13例世界卫生组织(WHO)I级和4例WHO II级脑膜瘤。PET和血样中根据血液放射性归一化后的SUV和SUV,以及V能够显著区分WHO分级,最大和平均肿瘤与全血比值的结果最佳(敏感性100%,特异性94-95%,准确性99%;P = 0.003)。静态[F]FLT指标与增殖生物标志物显著相关,尤其是Ki-67指数、phh3和TK1,而与VEGFA或V无相关性。使用Ki-67指数阈值>4%时,大多数[F]FLT指标显示出较高能力识别侵袭性脑膜瘤,SUV表现最佳(敏感性80%,特异性81%,准确性80%;P = 0.024)。
[F]FLT PET可能是评估脑膜瘤细胞增殖的一种有用的成像方式。